See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Liberation Day
Tariffs
Donald Trump
Trade War
Natural Disasters
Baseball
Senate
Republican Party
Social Media
Artificial Intelligence
Democratic Party
Tennis
Published • loading... • Updated

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Summary by News Medical
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

6 Articles

All
Left
Center
1
Right
News MedicalNews Medical
Center

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

·United States
Read Full Article
Neuroendocrine Cancer UKNeuroendocrine Cancer UK

Center of Excellence Outreach

Can you help us with reaching out to the Centres of Excellence? With your help we will be able to highlight the full range of support and services we offer to the centre of excellence teams and encourage them to inform their patients about our services. Our ask of you: By acting as a ‘bridge’

Read Full Article
Pharmaceutical Business reviewPharmaceutical Business review

US FDA approves Exelixis’ Cabometyx for advanced neuroendocrine tumours

The FDA’s approval adds to its five prior approvals and is based on positive outcomes from the CABINET Phase III trial. CABINET is a multicentre, randomised, double-blinded, placebo-controlled The post US FDA approves Exelixis’ Cabometyx for advanced neuroendocrine tumours appeared first on Pharmaceutical Business review.

Read Full Article
ajmc.comajmc.com

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

Read Full Article
oncnursingnews.comoncnursingnews.com

Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

Read Full Article
targetedonc.comtargetedonc.com

FDA Approves Cabozantinib for Advanced Neuroendocrine Tumors

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extrapancreatic neuroendocrine tumors.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)

Similar News Topics

Medical

Medical

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal